Cytokines are important modulators of host antitumor responses. Two of these cytokines, interleukin-2 (IL-2) and interferon y (IFN-y), are produced after antigen-induced activation of helper lymphocytes. The cytokines are released into the immediate vicinity where they either interact with the appropriate receptors on effector cell populations or are rapidly degraded. To mimic this physiologic release of cytokines at the effector-target site, we used retroviral vectors to transduce melanoma cells with the IL-2 or IFN-y cDNA. Five melanoma cell lines were transduced with IL-2-or IFN-ycontaining vectors and secreted IL-2 at 1 to 40 U/mL/106 cells/24 h or IFN-y 1 to 8 U/mL/106 cells/24 h, respectively. After y irradiation, these cells continued to secrete cytokines for about 3 to 4 weeks. Secretion of IFN-y induced upregula-URRENT therapeutic approaches for metastatic mel-C anoma are inadequate. Therapeutic approaches that aim to amplify the patient's own immune response have received considerable attention based on evidence in animal models of protective immune responses to a tumor cell challenge following appropriate immunizati~n.l-~ Whereas vaccination protocols in cancer patients have not shown a clear impact on patient survival, evidence in several trials suggests that patients who develop immune responses have a significant improvement in disease-free survival and overall survival compared with nonresponders6-13 A major aim of vaccination trials has been to induce serologic and cytotoxic T-cell (CTL) responses. Although blood and tumor infiltrates from melanoma and renal cell carcinoma patients contain circulating cytotoxic precursor cells with restricted reactivity for autologous melanoma14-'* and renal cell carcinoma^,^^-^^ it has been difficult to show that vaccination induces or amplifies serologic or CTL responses. Several hypotheses exist, such as tumor cells are poor antigen-presenting cells, they have low or absent major histocompatibility complex (MHC) molecules expressed on the cell surface, they secrete suppressor factors, or that T-cell receptor (TCR) engagement by the tumor antigens without a costimulatory signal induces anergy. Interleukin-2 (IL-2) can reverse two of those mechanisms. First, IL-2 can reverse suppression of CTL responses induced by tumor growth factor+ (TGF-p).26 Second, engagement of the TCR without a proliferative signal can induce anergy, but the presence of IL-2 may prevent this anergy from d e v e l~p i n g .~~~~~ We and other investigators have shown that the introduction of cytokine genes into murine tumor cells induced increased immunogenicity and decreased tumorigeneSecretion of IL-2 or interferon-y (IFN-7) by a murine fibrosarcoma led to a T-cell-mediated response that resulted in rejection of the t~m o r .~~,~~ Human melanoma15J6,38,39 is an especially promising candidate for this strategy of active immunization. Cytotoxic T-cell clones specific for autologous melanoma cells can be generated in patients by stimulating peripheral blood mononuclear cells with tumor cells in the presence of IL-2. In addition, shared melanoma antigens recognized by CTL in the context of specific MHC haplotypes (eg, HLA-A1 and HLA-A%) have been identified.l4-l8 Recently, a gene encoding a melanoma antigen recognized by autologous CTL was cloned from a cosmid library made from cDNA of melanoma cells.@ These studies and others provide evidence that shared melanoma epitopes exist that are recognized by T cells, implying that allogeneic melanoma cells might be suitable for use in vaccination p r o t o~o l s .~~~~~,~2
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Based on evidence that there are shared tumor antigens in m e l a n~m a , '~J~,~~,~~ that cytokine secretion by tumor cells increases i m m~n o g e n i c i t y ,~~-~~ that the frequency of CTL precursors in melanoma patients can be as high as 1:900,43 and that in vivo secretion of IL-2 by tumor cells increased the frequency of circulating cytotoxic precursors and of CTLs specific for the immunizing tumor in a murine model,31 we decided to use gene transfer technology to induce melanoma cells to secrete IL-2 or IFN-y. These cells could potentially be administered to appropriately HLAmatched patients and lead to amplification of existing cytotoxic T-cell precursors.
Our results show that melanoma cells stably secrete these cytokines following retroviral-mediated gene transfer. In addition, lymphokine secretion was maintained following irradiation of the cells, an important precaution when these 2818 GANSBACHER ET AL cells are injected in vivo in clinical trials. Finally, these cytokines showed a biological effect in vitro and in vivo in nude mice. These findings provide a logical basis for designing approaches for active immunotherapy in humans.
MATERIALS AND METHODS
Cell lines and tissue culture. Five human melanoma cell lines were selected for this study. The cell lines SK-MEL-19,-29,-131, -245,-256 were established from primary tumor specimens or metastatic lesions and were obtained from our cell bank (Memorial H o~p i t a l ) .~-~~ Cell lines were cultured in Eagle's minimum essential medium (MEM), 2 mmol/L glutamine, 1% nonessential amino acids, 100 U/mL penicillin, and 100 pg/mL streptomycin supplemented with 10% fetal bovine serum (FBS). Cultures were regularly tested for mycoplasma.
The retroviral vectors N2/IL2, DC/TK/IL2, N2/CMVIL2, and DCA used in this study are identical to the ones used in our murine fibrosarcoma tumor modeLZ9 DC/AD/R/IL2 was generated by cloning a minigene containing the human adenosine deaminase (ADA) promoter, the human IL-2 cDNA, and the poly-A sequences into the 3' long terminal repeat (LTR) in reverse orientation. The ADA promoter is an 832-bp fragment derived from the human ADAgene by digestion with restriction enzymes Ssp I and Nco I and was cloned in reverse orientation into the Klenowed Mlu I site. The poly-A signal, containing a 275-bp long Sma I-Alu I fragment, was derived from plasmid PBC/CMV/IL2 and cloned into the Klenowed Apa I site of the 3' LTR p~lylinker.~' The human IL-2 cDNA used for this construct was cloned by polymerase chain reaction (PCR) from peripheral lymphocytes of a healthy volunteer. Sequencing of the IL-2 cDNA showed a polymorphic site in position 456 (G for A) that does not lead to a change in the amino acid sequence. Retroviral vector constructs were converted to corresponding virus using established procedures. Briefly, vector CMVINF-y, DCA and DC/AD/R/IL-2) was transfected into a helper-free, amphotropic packaging cell line.48%49 Colonies were isolated by G418 selection, expanded to cell lines, and cell-free supernatant was tested for the presence of virus. Cell lines secreting a high titer of virus (los to 106 neocolony-forming U/mL) were used to infect melanoma cell lines. Bulk and clonal derivates of melanoma cells were isolated by G418 selection, expanded to cell lines, and secretion of IL-2 or IFN-y into the cell supernatant was measured. Absence of replication-competent virus in the cytokine-producing melanoma cells was shown by the inability to transfer G418 resistance to NIH 3T3 cells and by a negative reverse transcriptase assay in the HeLa and NIH3T3 amplification assay.
High molecular weight DNA was prepared from the tumor cells by standard techniques involving sodium dodecyl sulfate (SDS), protein kinase digestion, phenol extraction, and ethanol precipitation. Each analysis was performed on 10 kg of DNA. The samples were electrophoresed and transferred to a nylon filter (Biotrans; ICN Flow, Costa Mesa, CA). Filters were hybridized using the NeoR probe (New England Biolabs, Inc, Boston, MA) labeled by a random primer method.s0 After hybridization the filters were washed and exposed to Kodak XAR (Eastman Kodak, Rochester, NY) roentgenogram films.
Poly-A RNA was prepared from total cellular RNA using oligo(dT)-cellulose columns. The RNA was size fractionated on a 1% agarose gel containing formaldehyde, transferred to a nylon filter (Biotrans, ICN Flow) and UV-cross-linked to the filter. Hybridization was performed for 24 hours as previously described?l using a cDNA probe for U3 labeled by the random primer method.50 The filter was washed under stringent conditions,
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blotted dry, wrapped in Saran Wrap, and exposed at -70°C to Kodak XAR roentgenogram film with an intensifying screen.
Supernatants from 2 x lo6 semiconfluent unmodified or IL-2-secreting cells were collected after 24 to 48 hours and were assayed for human IL-2. Preparations of IL-2 were tested for biologic activity by assessing their ability to induce incorporation of 3H-thymidine (TdR) into the DNA of IL-2-dependent cultured T cells (CTC) in a proliferation assay as previously described.s2 Units are given in Cetus units. Results were confirmed by immunoassay using an ELISA kit (Genzyme Corp, Boston, MA). Briefly, 50,OOO CTC were mixed with serial dilutions of the test samples and cultured at 37°C in 5% C02. After approximately 60 hours the cultures were pulsed with 1 pCi 3H-TdR (New England Nuclear, Boston, MA; specific activity 6.7 Ci/pmol/L) for the final 12 hours of growth.
Supernatants were analyzed for IFN-y in a bioassay based on the antiviral activity in the cell culture supernatant, as determined by the reduction of the cytopathic effects of vesicular stomatitis virus on WISH ~e l l s . 5~ Results were confirmed using a commercially available radioimmunoassay (RIA) for human IFN-y (Centocor, Malvern, PA). Human IFN-y bioactivity in the supernatant was blocked by a neutralizing murine monoclonal antibody (MoAb) specific for human IFN-y (Olympus Corp, Lake Success, NY).
Two hundred thousand cells were resuspended in phosphate-buffered saline (PBS) containing 2% FBS, 0.02% sodium azide, and distributed into microtiter wells. The cells were centrifuged and the supernatant was poured off. One hundred microliters per lo6 cells of diluted MoAb W6/32 directed against a monomorphic determinant on the MHC class I molecule was then added, and the cells incubated on ice for 30 minutes. The cells were washed three times with 100 pL cold PBS as described above and, after gently breaking up the cell pellet, 100 pL/106 of fluorescein isothiocyanate (F1TC)-conjugated goat antimouse IgG were added to each sample. The cells were incubated on ice in the dark for another 30 minutes and washed as described above. They were immediately analyzed for percent fluorescence with an Epics C cytometer (Coulter Electronics, Inc, Hialeah, FL) equipped with logarithmic amplifiers for fluorescence measurements. Fluorescence originating from dead cells was eliminated by threshold gating of forward and 90" light scatter ~ignals.5~
Parental and lymphokine-secreting melanoma cells were irradiated at room temperature with a 6-mV Varian CL6-100 linear accelerator at a dose-rate of 1 Gy/min and then plated in several 60-mm dishes at identical concentrations. Irradiated cells were cultured at 37°C in 5% COz atmosphere. Cells were refed with 3 mL/dish of fresh RPMI containing 10% fetal calf serum (FCS) every 3 to 4 days and supernatants collected at the indicated time points. Spent medium was frozen at -20°C until assaying. After supernatant collection cells were trypsinized and counted. One milliliter of the experimental sample was mixed with 3 mL of Dulbecco's MEM, 10% FCS, 5 mmol/L glutamine, and polybrene 8 pg/mL and added to a 60-mm plate containing 1@ NIH3T3 cells passaged 12 hours previously. Infected NIH3T3 cells were cultured for 21 days, passaging the cells at a 1 5 dilution every 3 days. One half of this cell population was assayed for G418 resistance the other sample was used for collection of supernatant for determination of reverse transcriptase activity. Reverse transcriptase activity was determined by incubating 10 kL of sample media with 40 p L 50 mmol/L Tris, pH 8.0,20 mmol/L dithiothreitol (DTT), 0.6 mmol/L MnC12,60 mmol/L NaCI, 0.05% Nonidet P-40 (NP), 5 pg/mL oligo dT, 10 kg/mLpoly-A, 62 pmol/L thymidine-5-triphosphate (dTTP), 10 kmol/L P32 dTTP (3,000 Ci/mmol/L) for 1 hour at 37°C. Medium alone was used as negative control to determine back- 
RESULTS
Generation of tumor cell lines expressing IL-2 or IFN-y. Figure 1 shows the retroviral vector constructs that were used to introduce and express the human IL-2 or IFN-y genes in tumor cells. All were derived from Moloney murine leukemia virus and are based on the high titer N2 retroviral vector, which also contains the bacterial neomycin resistance (Neo)-selectable gene. Table 1 lists the five human melanoma cell lines that were transduced with IL-2 or IFN-7 vector constructs. These cell lines include both pigmented and nonpigmented strains and represent both early and late stages of melanocyte Following growth in G418-containing medium, Southern blot analysis was used to show that an intact provirus was present. A Southern blot analysis from SK-MEL-29 cells transduced with DC/AD/R/IL2 is illustrated in Fig 2 to show that the proviral DNA was integrated in a nonrearranged form and that the transfer of the miniunit from the 3' to the 5' LTR had taken place. A Northern blot of transduced SK-MEL-256, representative of those obtained with three of the vectors used, is illustrated in Fig 3 to show that the transduced cells were expressing vector-specific RNA transcripts of the proper size. These include one unspliced transcript "V' consisting of the virion RNA and one spliced transcript "N" consisting of the Neo mRNA, both derived from the LTR, as well as one smaller transcript "P" originating from the internal promoter. Uninfected cells expressed none of these messages.
IL-2 and IFN-y secretion by tumor cells. Secretion of IL-2 or IFN-y by melanoma cells transduced with the retroviral vectors was determined using a bioassay and enzyme-linked immunoabsorbent assay (ELISA) for IL-2 and a bioassay and RIA for IFN-y (Table 1) . Data given in Table 1 are representative for transduced bulk-infected cell populations. Clonal populations were isolated and analyzed as well. The IL-2 produced by single clonal populations varied widely, ranging from 691 U/mL/106 cells to 0 U/mL/106 cells ( Table 2) . As expected from previous results, the cell lines varied in their expression and secretion of cytokines depending on the particular retroviral vector used. In all cases human IL-2 or IFN-y activity could be neutralized by an appropriate MoAb (data not shown). Melanoma cells transduced with the control vector DCA did not secrete detectable amounts of IL-2 or IFN-y (data not shown). Secretion of human IL-2 or IFN-y had no discernible effect on cell morphology, pigmentation, or growth rate in culture compared with parental cells or cells transduced with DCA (data not shown). Some of these transduced cell lines have been in culture longer than 6 months and have continued to secrete stable amounts of IL-2 or IFN-y.
In the context of immunotherapy, transduced cells injected intra- dermally could serve as a source both of continuous local cytokine production and of tumor antigen. Although cytokine-secreting tumor cells exhibit decreased tumorigenesis and would most likely not grow in vivo, we decided to test whether irradiating them as a further precaution would affect cytokine secretion. Our results showed that following irradiation with up to 10,000 rad, cytokine production 3 and Fig 4) . Postirradiation IL-2 secretion increased, possibly because of increased leakage from radiation-damaged cells (Table 3 ). The duration of IL-2 secretion was influenced by the amount of radiation delivered to the cells and in this way defined by the radiosensitivity of each cell line. The irradiated cell lines were incapable of growth in culture as shown by the decreasing cell number over time (Table 3 ). In addition, the irradiated IL-2-secreting tumor cells were not able to form tumors in nude mice. This has been a consistent finding in different tumor types.55 IFN-y secretion after irradiation was not tested, but in a human renal cell carcinoma model used to study the effect of IFN-y gene transduction, secretion of IFN-y persisted for several weeks after irradiation. 56 These results illustrate that it is possible to lethally irradiate the cells before injection into patients and continue to have cytokine secretion for several weeks.
persisted for 3 to 4 weeks (Table

IFN-y is able to upregulate surface expression of MHC antigens on a varieo of cell
Because antigen is recognized by T cells only when presented in the context of MHC class I or I1 molecules, it is believed that an important mechanism by which IFN-y exerts an antitumor effect is to upregulate antigen presentation by augmenting MHC expression. To test whether there was a biologic effect of IFN-y on MHC expression by melanoma cells, we examined MHC class I antigen expression after IFN-y transduction. We observed variable upregulation of MHC class I on the IFN-ysecreting melanoma lines. In analogy to observations described for IL-2, we observed a wide variation in IFN-y expression. Other investigators using one of the IFN-y vectors described in this report observed a similar finding in an experimental murine system.60 MHC class I was expressed on parental SK-MEL-131 tumor cells before infection and levels were upregulated following IFN-y gene transduction (Fig 5) . SK-MEL-245 and SK-MEL-256 also expressed HLA class I molecules on the cell surface. IFN-y secretion induced modest upregulation on SK-MEL-245, but not on SIC-MEL-256 cells. SK-MEL-19 did not express HLA class I molecules and IFN-y secretion had no effect (Fig 5) . Thus, upregulation of class I molecules after IFN-y transduction was variable, and induction of MHC must be evaluated on an individual basis.
To test cells representing a range of IL-2 secretion we chose to inject SK-MEL-29 and SK-MEL-245 cells, which secrete 40 and 2 U IL-2/mL/106, respectively, into nude mice. Groups of three BALB/c nu/nu mice were injected subcutaneously with 2.5 x lo5, 5 x lo5, and 1 x lo6 cells of parental or corresponding IL-2-secreting, bulk selected melanoma cell populations. We observed that all mice injected with parental cells developed palpable tumors within 4 weeks, whereas all mice injected with IL-Zsecreting tumor cells remained tumor-free during an observation period of 3 months (data not shown). None of the IL-2-secreting melanoma cell lines generated tumors in nude mice, showing that the secreted IL-2 was biologically active and suggesting that effector cells, possibly natural killer (NK) cells, are activated in vivo. IL-2-or IFN-y-secreting tumor cells irradiated with 10,000 rads and immediately injected into nude mice did not form tumors either. Nonirradiated IFN-y-secreting tumor cells formed tumors as expected because IFN-y action is species specific.6l
Replication-competent murine retroviruses may arise during the experimental procedures by recombination with endogenous retroviral-like sequences. The presence of replicationcompetent murine retrovirus was assayed in a group of transduced tumor cell lines. Melanoma and renal cell carcinoma cell lines had been transduced 21 to 28 days previously with DC/AD/R/IL2 and the supernatants used to infect NIH3T3 cells. After growing the NIH3T3 cells for 21 days, G418 resistance and reverse transcriptase activity were assayed. No G418 resistance was detected. No reverse transcriptase activity was observed using the HeLa and NIH3T3 amplification assay (Fig 6) .
Growth in nude mice.
Replication-competent retroviruses are not generated.
DISCUSSION
In this report we show that it is possible to transduce human melanoma cells with the IL-2 or the IFN-7 gene using retroviral vectors and to induce them to secrete cytokines constitutively. Expression of a variety of cytokine genes, including IL-2,29-31 IL-4,35 IFN-y,33,62 IL-6,37 and CTLs have been shown to exert a tumoricidal effect on melanoma ceIls.38,39,63 Coulie et a1 reported that CTL precursors could be detected in the peripheral blood of melanoma patients, with a frequency ranging from 1/900 to 1/33,000.43 The frequency of cytotoxic precursors in these melanoma patients is in the range of that observed after successful immune responses against viruses such as cytomegalovirus, herpes simplex virus, and varicella These findings are important because they suggest vaccination protocols with the goal of increasing the frequency of CTLs, rather than inducing them de novo. Evidence that such expansion can occur was reported in the P815 tumor model in which in vivo secretion of IL-2 by the tumor cells increased the frequency of circulating tumor-specific CTLs twofold to fourfold. 31 We used four IL-2 constructs and two IFN-y constructs in these studies (Fig 1) . IL-2 and IFN-y were chosen because they previously showed efficacy in decreasing the tumorigenesis of cells that secrete them and because they act on both effector and tumor cells, possibly in a synergistic
As expected, cells infected with the recombinant vectors varied with respect to the amount of cytokine secreted (Table 1) . Within bulk-infected cells we found clones secreting from 0 U/mL to 691 U/mL/106 cells. If transduced tumor cells express a known tumor antigen such as MAGE-1, the highest IL-2 and MAGE-1 expressor clone can be selected for vaccination in the attempt to maximize clonal expansion of the MAGE-1-specific CTL population in vivo. If the tumor antigen is not known, it is reasonable to use bulk-selected cytokine-secreting tumor cells as vaccine to maintain antigenic heterogeneity.
Following irradiation with 10,000 rad, the cells continued to produce significant amounts of IL-2 for 3 to 4 weeks (Fig  4 and Table 3 ). y Irradiation actually caused increased cytokine release for a short period, possibly because of leakage of cytokines from dying cells. These observations may be important in clinical application in which it is desired to avoid injecting viable tumor cells into patients.
We observed that IFN-y secretion by tumor cells increased MHC class I expression in some lines but not in others, although the basis of this phenomenon is not apparent (Fig 5) . Because tumor antigens are presented to T cells in context of HLA class I'5J6,40 it will be important to select tumor cells that are IFN-y responsive for vaccination protocols.
Our results show a biologic effect in vivo, because the IL-Zsecreting cells were rejected in BALB/c nulnu mice, whereas the normal counterparts formed tumors. Because nude mice lack T cells but do have NK cells, we assume that NK cell-activation participated in tumor rejection. These results support only a notion that the secreted IL-2 is For personal use only. on September 24, 2017. by guest www.bloodjournal.org From melanoma a n t i g e n~. '~J~-~ Because 40% of the white population express the HLA-A2 molecules, the use of allogeneic melanoma cells that express HLA-A2 and shared melanoma antigens is an attractive strategy. In our study, SK-MEL-29, SK-MEL-245, and SK-MEL-256 (Table 1) express the HLA-A2 molecule. HLA-A2-matched melanoma patients would be candidates for such a vaccination protocol because most HLA-A2-positive melanomas express shared melanoma antigen.17 HLA-A-matched allogeneic irradiated tumor cells that secrete IL-2 have the potential to activate and to amplify cytotoxic effector cells that recognize peptides presented by autologous tumor cells in the context of matched HLA. Data published recently show an 80-fold more potent expansion of the antigen-specific clone if the antigen-presenting cells express the antigen with a costimulatory signal.2R
One of the cell lines described in this report, SK-MEL-29, has already been used as an allogeneic vaccine in 17 melanoma patient^.^ SK-MEL-29 expresses well-characterized melanocyte differentiation antigens. None of the vaccinated patients developed an antibody response against these differentiation antigens, documenting that irradiated tumor cells alone are inadequate as stimulators of a humoral antitumor response. Induction of high affinity IgG responses requires CD4+ T-cell help. Thus, high affinity IgG production against melanocyte differentiation antigens would also be an indication that such vaccination could activate host T cells.
Despite the supporting experimental data, a vaccination approach using IL-2-secreting tumor cells may fail. For example, irradiation may decrease immunogenicity of tumor cells, vector design may not be optimal and the amounts of IL-2 secreted could be insufficient, or tumor cells could secrete suppressor factors preventing successful expansion of CTL. Systematic approaches to each of the potential problems will be needed. Our present results show that retroviral vectors can be used to introduce cytokine genes into human tumor cells. The transduced tumor cell lines can be maintained in culture for several months during which time they continue to secrete cytokines in a stable manner. Rejection of IL-2-secreting tumors by nude mice and upregulation of MHC class I genes on some of the tumor cells shows that the secreted cytokines are biologically active. These data provide scientific and practical support for active vaccination protocols using retroviral cytokine gene transfer in an attempt to increase the frequency of preexisting cytotoxic precursors in the circulation of tumor bearing patients. biologically active and do not predict the effect on a CTL population. We used human IFN-y-secreting tumor cells as a control to exclude the possibility that other factors induced by the retroviral infection would be responsible for tumor rejection. IFN-y action is species specifich1 and melanoma cells secreting human IFN-y formed tumors identically to parental melanoma cells.
These experimental data show that IL-2-or IFN-ysecreting melanoma cells are available for clinical use. Autologous cells may or may not be preferable to allogeneic cells for vaccination protocols, however, in only 20% to 30% of melanoma patients can tumor cell lines be established. Because shared tumor antigens are MHC class I r e s t r i~t e d , '~J~.~ it should be possible to use established allogeneic cell lines transduced with cytokine genes for vaccination. At least two MHC class I molecules, HLA-A1 and HLA-A2, have been described to present shared
